Financial Performance - The company's revenue for Q3 2023 reached ¥2,920,138,789.43, representing a year-on-year increase of 5.49%[4] - The net profit attributable to shareholders for Q3 2023 was ¥352,944,967.45, a decrease of 6.05% compared to the same period last year[4] - The adjusted net profit attributable to shareholders under non-IFRS was ¥480,583,101.41, down 6.82% year-on-year[4] - Total revenue for the period reached ¥8,560,256,911.27, an increase of 15.6% compared to ¥7,402,793,998.96 in the previous period[26] - The net profit for Q3 2023 was CNY 1,134,523,142.41, an increase of 20.2% compared to CNY 944,178,254.54 in Q3 2022[27] - The company reported a total comprehensive income of CNY 1,107,456,956.68 for Q3 2023, compared to CNY 899,030,529.31 in Q3 2022, marking a growth of 23.2%[28] - Basic earnings per share for Q3 2023 were CNY 0.6430, up from CNY 0.5412 in the same period last year, representing an increase of 18.8%[28] Revenue Sources - Revenue from the top 20 global pharmaceutical companies amounted to approximately ¥124,923.91 million, a year-on-year increase of 5.44%[10] - Revenue from overseas laboratories and factories grew by 26.70% year-on-year, accounting for 13.34% of total revenue[9] - Revenue from clinical research services reached ¥1,262,099,160.97, marking a year-on-year increase of 28.48%[8] Cash Flow and Assets - The company reported a net cash flow from operating activities of ¥2,029,402,975.72, reflecting a significant increase of 45.47% year-to-date[4] - Cash and cash equivalents rose by 37.48% to ¥2,058,719,211.34, with an increase of ¥56,123.54 million from the previous year[13] - The total assets at the end of Q3 2023 were ¥22,476,012,563.70, an increase of 9.68% from the end of the previous year[4] - The cash flow from operating activities generated a net amount of CNY 2,029,402,975.72, compared to CNY 1,395,070,031.14 in the previous year, indicating a significant increase of 45.4%[29] - The cash and cash equivalents at the end of Q3 2023 amounted to CNY 2,022,842,617.58, an increase from CNY 1,691,911,763.98 at the end of Q3 2022[30] Expenses and Liabilities - Total operating costs amounted to ¥7,354,768,450.44, up from ¥6,289,455,335.33, reflecting a year-over-year increase of 16.9%[26] - The total liabilities increased to ¥9,749,326,551.15 from ¥9,652,689,512.90, reflecting a rise of 1.0%[25] - The company's total operating expenses increased to CNY 10,928,665.52, down from CNY 17,687,425.20 in Q3 2022, indicating improved cost management[27] Research and Development - R&D expenses increased by 67.22% to ¥296,764,121.85, reflecting the company's commitment to enhancing R&D capabilities and technical expertise[14] - Research and development expenses increased significantly to ¥296,764,121.85, compared to ¥177,468,493.98, marking a growth of 67.1%[26] Shareholder Information - Total number of common shareholders at the end of the reporting period is 66,106[16] - The top 10 shareholders hold a total of 1,020,000,000 shares, representing approximately 61.54% of total shares[16] - HKSCC NOMINEES LIMITED holds 16.87% of shares, amounting to 301,502,038 shares[16] - Shenzhen Xinchengkang Investment Partnership holds 14.63% of shares, totaling 261,427,958 shares[16] - Pharmaron Holdings Limited owns 10.10% of shares, equating to 180,496,500 shares[16] Future Outlook - Future outlook includes continued investment in R&D and potential market expansion strategies to enhance growth[26] - The company continues to expand its integrated pharmaceutical R&D services globally, maintaining a focus on customer-centric strategies[9]

Financial Performance - Q3 2023 revenue reached ¥2,920,138,789.43, an increase of 5.49% year-over-year, while year-to-date revenue totaled ¥8,560,256,911.27, up 15.64% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2023 was ¥352,944,967.45, a decrease of 6.05% year-over-year, with year-to-date net profit at ¥1,139,038,016.10, an increase of 18.51%[4] - Total revenue for the nine months ended September 30, 2023, was RMB 8,560,257,000, an increase from RMB 7,402,794,000 in the same period of 2022, representing a growth of approximately 15.6%[45] - Net profit attributable to the owners of the parent company for the period was RMB 1,139,038,000, up from RMB 961,107,000 in the previous year, marking an increase of about 18.5%[45] - Basic earnings per share for the period was RMB 0.6430, compared to RMB 0.5412 in the same period of 2022, showing an improvement of approximately 18.8%[45] Revenue Breakdown - Revenue from laboratory services for the first three quarters of 2023 was ¥5,069,130,773.99, a year-over-year increase of 13.65%[5] - Revenue from CMC (small molecule CDMO) services was ¥1,913,656,858.43, with a year-over-year increase of 13.94%[5] - Revenue from clinical research services reached ¥1,262,099,160.97, reflecting a year-over-year growth of 28.48%[5] - Revenue from the top 20 global pharmaceutical companies was approximately ¥124,923.91 million, a year-over-year increase of 5.44%, accounting for 14.59% of total revenue[6] - Revenue from overseas laboratories and factories grew by 26.70%, representing 13.34% of total revenue[6] Profitability Metrics - The gross profit margin for laboratory services was 44.38% in the first three quarters of 2023, compared to 45.02% in the same period last year[5] - The company's main business gross margin for the first three quarters of 2023 was 35.97%, slightly down from 36.49% in the previous year[6] - Gross profit for the same period was RMB 3,059,800,000, compared to RMB 2,687,250,000 in 2022, indicating a gross margin improvement[45] Cash Flow and Assets - Cash flow from operating activities for the year-to-date period was ¥2,029,402,975.72, an increase of 45.47% compared to the previous year[4] - The net cash flow from operating activities increased by 45.47% to CNY 2,029,402,975.72 compared to the same period last year[10] - Cash inflow from investment activities totaled ¥2,107,544,066.88, down from ¥3,924,361,583.36 in the previous period[42] - As of September 30, 2023, total assets reached CNY 22.48 billion, an increase from CNY 20.49 billion at the beginning of the year, reflecting a growth of approximately 9.7%[21] - Current assets amounted to CNY 7.22 billion, up from CNY 6.54 billion, indicating a growth of about 10.4%[22] Liabilities and Equity - Total liabilities were reported at CNY 9.75 billion, slightly increasing from CNY 9.65 billion, representing a growth of approximately 0.9%[25] - The company's equity attributable to shareholders rose to CNY 11.90 billion from CNY 10.55 billion, marking an increase of around 12.8%[26] - Non-current liabilities increased to RMB 6,036,403,000 from RMB 5,740,256,000 at the beginning of the year, reflecting a rise of approximately 5.2%[48] Research and Development - R&D expenses rose by 67.22% to CNY 296,764,121.85, reflecting the company's commitment to enhancing R&D capabilities[12] - Research and development expenses increased to ¥296,764,121.85, a rise of 67.1% from ¥177,468,493.98 in the previous period[30] Shareholder Information - The total number of common shareholders at the end of the reporting period was 66,106, with no preferred shareholders[14] - The top ten shareholders hold a combined 53.11% of the shares, with HKSCC NOMINEES LIMITED holding the largest share at 16.87%[15] - The total number of restricted shares at the beginning of the period was 48,169,260, with 21,420,000 shares added during the period, resulting in a total of 64,260,000 restricted shares at the end[18] Other Financial Metrics - The company reported a basic earnings per share of 0.6430, compared to 0.5412 in the previous period, reflecting a growth of 18.8%[37] - The company incurred a financial expense of ¥108,844,237.57, down from ¥161,865,447.67 in the previous period, showing a decrease of 32.7%[30] - The total amount of non-operating income and expenses was CNY 24,393,822.75 for the current period[7] - The company reported a profit before tax of RMB 1,320,946,000 for the nine months ended September 30, 2023, compared to RMB 1,207,470,000 in the same period of 2022, reflecting a year-over-year increase of approximately 9.4%[45]

Financial Performance - For the six months ended June 30, 2023, the company recorded total revenue of approximately RMB 5,640.1 million, an increase of about RMB 1,005.5 million or 21.7% compared to the same period in 2022[10]. - The gross profit for the same period was RMB 2,037.4 million, representing a gross margin of 36.1%, which is an increase of 1.3 percentage points year-on-year[14]. - Profit attributable to equity holders of the parent was approximately RMB 786.1 million, reflecting a growth of 34.3% compared to the previous year[11]. - The net cash flow from operating activities was approximately RMB 1,280.2 million, an increase of 49.1% compared to the same period in 2022[11]. - Basic earnings per share increased by 34.9% to RMB 0.4442, while diluted earnings per share rose by 34.7% to RMB 0.4436[33]. Client and Revenue Breakdown - The company served over 2,140 global clients during the reporting period, with clients using multiple service segments contributing RMB 3,902.0 million, accounting for 69.2% of total revenue[15]. - Revenue from the top 20 global pharmaceutical companies was approximately RMB 850.3 million, a year-on-year increase of 27.7%, representing 15.1% of total revenue[15]. - Revenue from North American clients was approximately RMB 3,675.5 million, a year-on-year increase of 20.8%, accounting for 65.2% of total revenue[15]. - Revenue from European clients (including the UK) was approximately RMB 859.8 million, a year-on-year increase of 36.5%, representing 15.2% of total revenue[15]. - The company added over 400 new clients during the reporting period, contributing approximately RMB 222.9 million in revenue[15]. Operational Highlights - As of June 30, 2023, the company's backlog of orders increased by over 15% compared to December 31, 2022[16]. - The company's laboratory services generated revenue of 3,380.4 million yuan, a year-on-year increase of 21.7%, with a gross margin of 44.8%, up 1.2 percentage points[19]. - The biological sciences segment achieved over 35% growth, contributing more than 51% to the laboratory services revenue[19]. - The CMC (small molecule CDMO) services reported revenue of 1,251.3 million yuan, a 15.4% increase year-on-year, with a gross margin of 32.2%[23]. - Clinical research services generated revenue of 805.2 million yuan, a significant year-on-year increase of 37.7%, with a gross margin of 17.0%, up 11.9 percentage points[26]. Corporate Governance and Shareholder Information - The board of directors resolved not to declare any interim dividend for the six months ended June 30, 2023[11]. - The company is committed to maintaining high levels of corporate governance, ensuring shareholder interests are protected[106]. - The company has established an Audit Committee consisting of three members, with Mr. Yu Jian serving as the chairman[120]. - As of June 30, 2023, Pharmaron Holdings Limited directly held 120,331,000 A-shares, representing 12.15% of the total share capital[123]. - The major shareholders include CITIC Securities Co., Ltd. with 208,294,876 A-shares, accounting for 21.04% of the total share capital[128]. Employee and Workforce Development - As of June 30, 2023, the total number of employees increased to 19,733, with 17,689 in R&D, production technology, and clinical services, representing 89.6% of the workforce[16]. - The management team consists of experienced professionals, with over 17,689 R&D, production technology, and clinical service personnel across China, the UK, and the US as of June 30, 2023[70]. - The company is committed to attracting and retaining top talent to support long-term sustainable development, with a focus on training and development programs[84]. - The management team is committed to employee development, integrating personal career growth into the company's overall strategy[71]. Strategic Initiatives and Future Plans - The company is expanding laboratory facilities, including a 140,000 square meter lab in Ningbo expected to be operational in the second half of 2023[22]. - The company aims to enhance project management capabilities and improve collaboration across different disciplines in drug development to maximize client benefits[54]. - The company plans to enhance its integrated service platform for large molecule drugs and cell gene therapy, focusing on expanding its customer base and improving operational efficiency[81]. - The company will continue to develop its clinical development integrated platform to enhance clinical research service capabilities across its subsidiaries[83]. - The company emphasizes the importance of a strong talent development platform to support its strategic goals and enhance core competitiveness[83]. Market Outlook and Industry Trends - The global and Chinese pharmaceutical research and production investment is expected to maintain a good growth momentum, driven by an aging population and increasing healthcare spending[74]. - The drug research and production outsourcing service market is anticipated to grow rapidly, with large pharmaceutical companies increasingly outsourcing to reduce costs and improve efficiency[75]. - The global pharmaceutical industry is expected to grow due to factors such as aging populations and increased healthcare spending, although there are risks of slower growth impacting client R&D budgets[88]. Risk Management - The company faces foreign exchange risks primarily related to USD, GBP, and EUR, as a significant portion of its revenue is generated in foreign currencies while costs are incurred in RMB[96]. - To manage currency fluctuation risks, the company engages in hedging transactions[98]. - Regulatory compliance is crucial, as failure to meet the requirements of various health authorities could lead to operational restrictions or penalties[91]. - The company has been increasing its overseas service capabilities since 2015 to mitigate risks associated with international trade tensions and policy changes[94]. Share Incentive Plans - The company has granted a total of 2,203,200 restricted A-shares under the 2022 A-share incentive plan, which represents approximately 0.12% of the total issued shares as of the mid-term report date[161]. - The 2023 A-share incentive plan was approved by the shareholders' meeting and became effective on June 21, 2023, aiming to enhance corporate governance and retain key personnel[169]. - The maximum number of restricted A-shares to be granted under the initial award of the 2023 A-share incentive plan is 1,444,500 shares, accounting for approximately 0.08% of the total issued shares[172]. - The performance targets for the first batch of shares require a 20% increase in revenue for the year ending December 31, 2023, compared to the year ending December 31, 2022[175]. - The company recorded share-based compensation expenses of RMB 91,531,000 for the six months ended June 30, 2023, compared to RMB 23,755,000 for the same period in 2022, reflecting an increase of approximately 284%[193].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 就2023年第一次臨時股東大會 及2023年第二次H股類別股東大會 暫停辦理股份過戶登記手續 康龍化成（北京）新藥技術股份有限公司（「本公司」）董事會謹此宣佈，為釐定有 權出席謹定於2023年9月15日（星期五）下午2時30分舉行的2023年第一次臨時股 東大會（「臨時股東大會」）及2023年第二次H股類別股東大會（「H股類別股東大 會」），並於會上投票的本公司H股（「H股」）股東名單，本公司將於2023年9月12 日（星期二）至2023年9月15日（星期五）期間（包括首尾兩日）暫停辦理H股股份過 戶登記手續，該期間將不會辦理H股股份過戶登記手續。於2023年9月12日（星期 二）名列本公司股東名冊的H股股東將有權出席臨時股東大會及H股類別股東大會 並於會上投票。 為符合資格出席臨時股東大會及H股類別股東大會並於會上投票，所有H股過戶文 件連同有關股票須於2023年9月11日（星期一）下午4時30分前送 ...

Financial Performance - The company's revenue for the first half of 2023 reached ¥5,640,118,121.84, representing a 21.70% increase compared to ¥4,634,585,435.95 in the same period last year[25]. - Net profit attributable to shareholders was ¥786,093,048.65, up 34.28% from ¥585,432,372.85 year-on-year[25]. - The net cash flow from operating activities increased by 49.07% to ¥1,280,204,984.20, compared to ¥858,787,414.99 in the previous year[25]. - Basic earnings per share rose to ¥0.4442, a 34.85% increase from ¥0.3294 in the same period last year[25]. - Total assets at the end of the reporting period were ¥22,390,081,836.72, reflecting a 9.26% increase from ¥20,492,557,228.07 at the end of the previous year[25]. - The net assets attributable to shareholders increased by 9.35% to ¥11,535,328,562.32 from ¥10,548,615,357.20[25]. - The company reported a diluted earnings per share of ¥0.4436, which is a 34.71% increase from ¥0.3293 year-on-year[25]. - The weighted average return on equity improved to 7.09%, up from 5.69% in the previous year[25]. Operational Highlights - The company served over 2,140 global clients, with revenue from clients using multiple service segments amounting to CNY 3,901.97 million, accounting for 69.24% of total revenue[35]. - Revenue from North American clients was approximately CNY 3,675.47 million, a year-on-year increase of 20.81%, representing 65.17% of total revenue[36]. - The laboratory services segment generated revenue of CNY 3,380.37 million, a growth of 21.68% year-on-year, with a gross margin of 45.05%[39]. - The CMC (small molecule CDMO) services segment achieved revenue of CNY 1,251.32 million, a year-on-year increase of 15.37%[41]. - Clinical research services achieved revenue of 805.19 million yuan, a year-on-year increase of 37.75%, with a gross margin of 16.98%, up 11.87 percentage points from the previous year[43]. - The number of ongoing clinical trial projects reached 912, including 74 Phase III trials and 400 Phase I/II trials[44]. Strategic Initiatives - The company is enhancing its integrated service platform to meet the growing demand for drug research and development outsourcing, particularly from small and medium-sized biotech firms[48]. - The company has established a comprehensive drug research and development service platform, covering small molecules, large molecules, and cell and gene therapies, to support clients' innovation projects[49]. - The company has integrated a drug metabolism and pharmacokinetics (DMPK) service platform, enhancing its global service network through the acquisition of Absorption Systems, solidifying its leading position in DMPK services[52]. - The company has developed a complete integrated platform from drug discovery to proof of concept (POC), enabling it to provide a full suite of services required for IND applications, thus accelerating drug development and reducing costs[53]. - The company is focused on expanding its market presence and enhancing its product offerings, as indicated by ongoing discussions with various investment firms[103]. Environmental Compliance - The company strictly adheres to various environmental protection laws and standards, including China's air and water pollution regulations, as well as the UK's Control of Pollution Act 1974 and the Clean Water Act in the US[121]. - The company has established a comprehensive environmental management system, ensuring compliance with discharge standards and monitoring pollution levels[129]. - The company has implemented measures to reduce waste and emissions as part of its sustainability strategy[134]. - The company is focused on improving its environmental performance and compliance with regulatory standards[134]. - The company has received multiple environmental impact assessment approvals for its drug research and development projects, with the latest approval for a platform project received on October 12, 2022[122]. Shareholder Engagement - The annual shareholder meeting had a participation rate of 48.34%, reflecting significant shareholder engagement[107]. - The company engaged with over 400 institutions and 450 participants during investor communications, indicating strong interest from the investment community[101]. - The company disclosed its 2023 performance forecast during communications with investors, emphasizing transparency in its financial outlook[101]. - The company is committed to maintaining strong governance practices, as evidenced by the detailed reporting of its shareholder meetings and resolutions[107]. Risk Management - The management team emphasizes the importance of risk awareness regarding forward-looking statements and future development plans[3]. - The company has a comprehensive risk management section detailing potential operational risks and corresponding mitigation strategies[3]. - The company faces risks related to a potential decline in demand for drug development services, which could adversely affect its performance[95]. - The company has a significant exposure to foreign exchange risks, particularly with USD, GBP, and EUR, due to a high proportion of revenue from overseas clients[97].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Pharmaron Beijing Co., Ltd.* 康龍化成（北京）新藥技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 截至2023年6月30日止六個月中期業績公告 財務摘要及要點 截至6月30日止六個月 2023年 2022年 變動 人民幣千元 人民幣千元 % 收益 5,640,118 4,634,585 21.7 毛利 2,037,441 1,613,111 26.3 母公司擁有人應佔利潤 786,093 585,432 34.3 母公司擁有人應佔非國際財務報告準則 經調整淨利潤 931,852 812,106 14.7 經營活動所得現金流量淨額 1,280,205 858,787 49.1 － 於報告期間，本集團錄得總收益約人民幣5,640.1百萬元，較截至2022年6 ...

康龙化成（北京）新药技术股份有限公司 章程 （ 2023 年 8 月） 中国 北京 | 第一章 | 总则 1 | | --- | --- | | 第二章 | 经营宗旨和经营范围 2 | | 第三章 | 股份 3 | | 第一节 | 股份发行 3 | | 第二节 | 股份增减和回购 5 | | 第三节 | 股份转让 7 | | 第四章 | 股东和股东大会 10 | | 第一节 | 股东 10 | | 第二节 | 股东大会的一般规定 14 | | 第三节 | 股东大会的召集 21 | | 第四节 | 股东大会的提案与通知 23 | | 第五节 | 股东大会的召开 26 | | 第六节 | 股东大会的表决和决议 30 | | 第五章 | 董事会 37 | | 第一节 | 董事 37 | | 第二节 | 董事会 41 | | 第三节 | 独立非执行董事 48 | | 第四节 | 董事会秘书 54 | | 第六章 | 经理及其他高级管理人员 56 | | 第七章 | 监事会 59 | | 第一节 | 监事 59 | | 第二节 | 监事会 60 | | 第八章 | 公司董事、监事、高级管理人员的资格和义务 62 | | ...

（以下无正文） [本页无正文，为《康龙化成（北京）新药技术股份有限公司独立董事关于关联 方资金占用及对外担保情况的专项说明和独立意见》的签署页] 1、公司在 2023 年半年度严格执行了《上市公司监管指引第 8 号——上市公 司资金往来、对外担保的监管要求》（证监发[2022]26 号）的规定。公司不存在 实际控制人及其他关联方违规占用公司资金的情况，也不存在以前期间发生延续 至报告期的实际控制人及其他关联方违规占用公司资金的情况。 2、公司在 2023 年上半年度不存在任何形式的违规对外担保事项，也不存在 以前期间发生延续至报告期的违规对外担保事项。 康龙化成（北京）新药技术股份有限公司独立董事 关于关联方资金占用及对外担保情况的专项说明和独立意见 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司独立董 事规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》等法律、行政法规、部门规章及规范性文件及《康龙化成（北京）新药 技术股份有限公司章程》（以下简称"《公司章程》"）等有关规定，我们作为康龙 化成（北京）新药技术股份有限公司（以下简称"公司"）的独立董事，本着为 ...

中国证券监督管理委员会于 2023 年 2 月 17 日发布了《境内企业境外发行证 券和上市管理试行办法》及相关指引（以下简称"境内新法规"），并于 2023 年 3 月 31 日起施行。中国证券监督管理委员会于 1994 年 8 月 27 日发布的《到境 外上市公司章程必备条款》及国务院于 1994 年 8 月 4 日发布的《关于股份有限 公司境外募集股份及上市的特别规定》（以下简称"境内旧法规"）废除失效。 证券代码：300759 证券简称：康龙化成 公告编号：2023-077 康龙化成（北京）新药技术股份有限公司 关于注册资本增加、修订《公司章程》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）于 2023 年 8 月 25 日召开了第三届董事会第二次会议，审议通过了《关于注册资本增加的议案》 《关于修订<公司章程>的议案》《关于股东大会授权公司董事会经办与注册资本 变更及<公司章程>修订相关事项的议案》。现将具体内容公告如下： 公司于 2023 年 6 月 21 日召开 2022 年年度股 ...

康龙化成（北京）新药技术股份有限公司 关于公司增加对全资子公司担保额度的公告 一、担保情况概述 （一）已审批的担保额度情况 公司第二届董事会第二十四次会议及 2022 年年度股东大会审议通过了《关 于公司 2023 年度对外担保额度预计的议案》，同意 2023 年度为控股子公司提供 不超过人民币 40 亿元（含等值外币，下同）的担保额度，担保情形包括：公司 为合并报表范围内各级子公司提供担保、合并报表范围内各级子公司之间相互提 供担保，其中为资产负债率大于等于 70%的公司提供担保额度为人民币 6 亿元， 为资产负债率小于 70%的公司提供担保额度为人民币 34 亿元。 （二）本次新增的担保额度情况 证券代码：300759 证券简称：康龙化成 公告编号：2023-076 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 康龙化成（北京）新药技术股份有限公司（以下简称"公司"或"康龙化成"） 于 2023 年 8 月 25 日召开第三届董事会第二次会议，审议通过了《关于公司增加 对全资子公司担保额度的议案》。具体情况公告如下： 为满足业务发展的资金需求，公司拟在对 ...